Sanofi Consumer Healthcare India reported a 13.3% rise in net profit to ₹68.8 crore for the second quarter. The company saw a 6.7% revenue growth, supported by a 12% jump in domestic sales and improved profit margins. This performance highlights the company's recent focus on brand investments following its 2024 demerger.
Detailed Coverage
Sanofi Consumer Healthcare India Ltd. reported a net profit of ₹68.8 crore for the second quarter, marking a 13.3% increase over the ₹60.7 crore recorded in the same period last year. Revenue from operations grew by 6.7% to ₹235.7 crore. The company’s performance highlights its transition since becoming an independent legal entity on June 1, 2024, following a demerger from Sanofi India Ltd.
Margin Expansion and Segment Trends
A notable highlight of the quarter was the significant improvement in operating profitability. The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA)—a metric used to gauge core operational efficiency—rose by 27.2% to reach ₹89.3 crore. This resulted in the EBITDA margin expanding to 37.9% compared to 31.8% in the previous year. The company attributed these gains primarily to a 12% growth in domestic sales, which management noted was supported by successful product relaunches and targeted brand investments. In contrast, the company saw a 9% decline in export sales, which it clarified was due to a high base effect from the prior year’s performance.
For the first half of the calendar year, the company has maintained a positive growth trend, with revenue from operations rising by 18% to ₹464.9 crore. Domestic sales contributed strongly with a 14% increase, while export sales grew by 27% during this six-month period, aided by a lower comparative base.
Strategic Context and Monitorables
Sanofi Consumer Healthcare operates in a highly competitive segment of the Indian market, focusing on over-the-counter and consumer health products. Since its separation from the parent pharmaceutical entity, the company has focused on building independent go-to-market capabilities. Managing Director Himanshu Bakshi noted that the company’s current strategy involves disciplined execution and continued investment in its brand portfolio to capture market share.
For investors, the key monitorables will be the company’s ability to sustain these improved margins amidst intense competition in the consumer healthcare space. As a recently demerged entity, maintaining consistent revenue growth in its domestic portfolio and managing the volatility of its export segment will be important factors. Future quarterly updates will help determine if the current margin expansion is sustainable or if it will be impacted by increased spending on marketing and distribution as the company scales its operations independently.